The objective of this study was to assess the effects of subcutaneous (sc) interferon beta-1a (IFNb-1a) on cognition in mildly disabled patients with relapsing-remitting multiple sclerosis (RRMS). Patients aged 18-50 years with RRMS (McDonald criteria; Expanded Disability Status Scale score 4.0) were assigned IFNb therapy at the physician's discretion and underwent standardized magnetic resonance imaging, neurological examination and neuropsychological testing at the baseline and regular intervals for up to three years. This analysis included 459 patients who received sc IFNb-1a (44 mcg: n ¼ 236; 22 mcg: n ¼ 223; three-year follow up was available for 318 patients). The hazard ratio for cognitive impairment over three years (44 mcg versus 22 mcg) was 0.68 (95% confidence interval [CI]: 0.480-0.972), suggesting a 32% lower risk with the higher dose treatment. At year 3, the proportion of patients who were cognitively impaired increased slightly from 23.5% at the baseline to 24.8% in the IFNb-1a 22 mcg treatment group, but remained stable at 15.2% in the IFNb-1a 44 mcg treatment group. The proportion of patients with cognitive impairment at year 3 was significantly higher in the 22 mcg group than in the 44 mcg group (P ¼ 0.03), although a trend was also seen at the baseline (P ¼ 0.058). Multivariate logistic regression (corrected for baseline cognitive deficits) indicated that treatment with the higher dose of IFNb-1a was predictive of lower cognitive impairment at three years (odds ratio: 0.51, 95% CI: 0.26-0.99) compared with the lower dose of IFNb-1a. These findings suggest that sc IFNb-1a may have dose-dependent cognitive benefits in mildly disabled patients with RRMS, and may support early initiation of high-dose IFNb-1a treatment.
Introduction
Cognitive impairment is a common symptom of multiple sclerosis (MS), occurring in approximately 40-65% of patients with MS. 1 Cognitive deficits may develop in all MS subtypes and at any disease stage, 2,3 including in patients without physical disability 4 or with clinically isolated syndrome. 5, 6 Memory, learning, attention and information-processing activities are most commonly affected by MS, which may reflect damage to specific brain areas. Impaired cognitive function can cause considerable disability in MS, independent of physical symptoms, and contributes to a poor quality of life (QoL). 7 In addition, fatigue and depression are common comorbidities of cognitive impairment and can further increase disability levels. 8 Although little is known about the natural history of cognitive impairment in MS, available data suggest that remission of cognitive symptoms is unlikely and that cognitive performance decreases with worsening disability. 9, 10 Cognitive impairment may also predict physical disability or indicate progressive disease in the absence of worsening physical symptoms. 11 Despite the high prevalence of cognitive impairment in MS, it is rarely assessed during routine patient management. Furthermore, treatment for cognitive impairment centres on symptomatic therapies, with few pharmacological options. The observation that some magnetic resonance imaging (MRI) disease measures, including lesion load and brain volume, 1 correlate with cognitive impairment, suggests that disease-modifying drugs (DMDs) that reduce lesion development may also prevent or delay cognitive decline. However, the potential cognitive benefits of DMDs in patients with MS are unconfirmed. 12, 13 The COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study was performed to evaluate the progression of cognitive decline in patients with early relapsing-remitting MS (RRMS) receiving treatment with interferon beta-1a (IFNb-1a), 22 or 44 mcg (Rebif Õ , Merck Serono S.A. -Geneva, Switzerland), administered subcutaneously (sc) three times weekly (tiw). Here, we report three-year cognition and clinical results from the study; two-year outcomes have been reported elsewhere. 14 
Methods
The COGIMUS study is a prospective, multicentre, observational, three-year cohort trial assessing cognitive function in Italian patients with RRMS treated with IFNb. Study enrolment started in September 2003 at the University of Catania, and in January 2004 at the other participating centres, and was completed in March 2005.
Patients
Eligibility criteria have been described in detail elsewhere. 15 Briefly, patients aged 18-50 years with a diagnosis of RRMS, according to the McDonald criteria 16 and an Expanded Disability Status Scale (EDSS) 17 score of 4.0, who were naı¨ve to DMD treatment and had not been taking corticosteroids in the prior 60 days, immunosuppressants in the prior six months, or other immunomodulators in the previous year, were eligible for the study. All patients at the 40 study centres who fulfilled the inclusion and exclusion criteria were invited to participate in the study. In accordance with Italian law, patients were not paid for participating in this study. Patients were not seeking neuropsychological (NPS) consultation for suspected cognitive problems, but were motivated to participate by the potential benefits of undergoing evaluations that would not be performed as part of routine clinical practice. All patients gave written informed consent prior to undergoing any tests not performed as part of their routine management. As only a small proportion of patients in this observational study were assigned treatment with sc IFNb-1b or im IFNb-1a, and several dropped out over the three years, it was more appropriate to compare outcomes between the groups of patients receiving the two doses of sc IFNb-1a than in all four study groups. The two groups of patients receiving sc IFNb-1a were of a similar sample size and represented the majority of the study population (83.5%); therefore, the analyses focused on outcomes in these 459 patients.
Treatment
Relapses were treated with corticosteroids and flulike symptoms (FLS) were treated with non-steroidal anti-inflammatory drugs or paracetamol. Concomitant therapies were recorded on the case-report form. DMDs other than the study drug were not permitted.
Evaluation of disease status
Patients underwent a baseline neurological examination to determine physical disability (EDSS score), and clinical history was recorded. In two-thirds of the participating centres, conventional, standardized brain MRI (1.5 Tesla scanner) was performed at the baseline to determine T1 gadolinium-enhancing, T1 hypointense and T2 hyperintense lesion volumes, grey and white matter volumes and total brain volume. Baseline MRI findings and correlations with cognitive impairment have been described elsewhere. 15 Clinical assessments (EDSS score and relapses) were repeated and safety data were collected every six months.
Neuropsychological evaluation
All patients underwent NPS evaluation at the baseline and every 12 months for three years. If patients were experiencing disease relapse at the time of scheduled NPS assessments, cognitive testing was delayed until 30 days after the last steroid injection. These assessments included Rao's Brief Repeatable Battery 10 and the Stroop Colour-Word Task (ST) 18 for cognitive domains (alternate, parallel versions of Rao's battery were used to minimize learning effects; alternate versions were administered in the order A, B, A, B to all patients), the Hamilton Depression Rating Scale, 19 the MSQoL-54 questionnaire 20 for QoL, the Fatigue Impact Scale 21 and the Environmental Status Scale 22 for social functioning. Patient intelligence quotient (IQ) was determined at the baseline by administering the Brief Intelligence Test, 23, 24 as described previously. 15 Cognitive impairment was defined as 1 SD below the mean Italian normative values for each cognitive test, as described previously in a study of 200 healthy volunteers. This normative population had a mean (SD) age of 41.5 (9.8) years, a male:female ratio of 1:2, and had spent a mean (SD) of 12.3 (3.6) years in education. 25 A cognitive impairment index was constructed at the baseline and year 3 for each patient using the mean and SD from the normative sample of Rao's battery 25 in order to confirm that cognitive impairment was correctly detected. A grading system was applied to each patient's score on each cognitive test, dependent on the number of SDs below the normative mean as described previously. 15, 26 
Study endpoints
The primary endpoint was the proportion of patients with cognitive impairment over three years in patients treated with different doses of sc IFNb-1a. In the absence of widely accepted guidelines for the assessment of cognitive function, cognitive impairment was defined as impaired performance on at least three cognitive tests. This definition for cognitive impairment has previously been shown to be sensitive to changes in cognitive function over time in a study of Italian patients with early MS, in which cognitive decline was compared in patients and healthy volunteers over 10 years of follow up. 7 In this study population, we found that the proportion of patients identified as having cognitive impairment at the baseline was similar when using either this definition or a definition based on fifth and 95th percentiles for the Rao's battery and the ST, respectively. 15 Additional endpoints were the change in cognitive impairment index score over three years and the assessment of factors predictive of cognitive impairment at three years. Other endpoints will be reported elsewhere. Discontinuations were recorded, and patients who discontinued treatment were followed up regularly in the clinical trial setting.
Statistical analyses
Descriptive analyses were performed at the baseline for the cohort of 459 patients treated with sc IFNb-1a. For outcome measures at three years, only patients with three years of follow up were included in the analyses. No imputation of missing data was considered. The Cox proportional-hazards model was used to compare cognitive impairment over three years. A multivariate regression model was developed by sequentially adding variables that had a significant hazard ratio in the univariate analysis. To account for the fact that all patients were entered into the analysis, the hazard ratio was evaluated using 'more than one time option shared' (STATA software). Kaplan-Meier survival curves were constructed to evaluate longitudinal differences between treatments.
The following tests were also conducted, with a significance level of 0.05. Chi-squared tests were performed to compare proportions. The Mann-Whitney test was used for the comparison of two independent samples. The Kazis' effect was calculated to assess the variability of the cognitive tests over time, using the calculation: (mean score at year 3 -mean score at baseline)/SD at the baseline. A positive result indicated an improvement and a negative result indicated a worsening in cognitive function over three years of treatment. The effect sizes are defined as: small, 0.20-0.49; moderate, 0.50-0.79; and large, 0.80-1.00. 27 The Wilcoxon test for paired samples was performed to evaluate changes over time in the cognitive impairment index.
Risk factors for cognitive impairment at three years were identified using univariate and multivariate logistic regression. Univariate logistic regression was performed for the following variables: the baseline characteristics shown in Table 1 ; the presence or absence of cognitive impairment at the baseline; and treatment group (IFNb-1a 22 or 44 mcg sc tiw). A multivariate regression model was then developed by sequentially adding variables with a significant odds ratio in the univariate analysis. Variables that remained significant were included in the final model.
Results

Patients and baseline characteristics
Here we report baseline characteristics and three-year outcomes from the 459 patients treated with sc IFNb-1a, of whom 223 (48.6%) received the 22 mcg dose and 236 (51.4%) received the 44 mcg dose. Descriptive data for the small subgroups of patients receiving im IFNb-1a or sc IFNb-1b are also provided.
Among the 459 patients receiving sc IFNb-1a, the mean (SD) age was 33.3 (8.13) years, and the male:female ratio was 1:1.87. The mean (SD) duration of disease was 3.8 (4.47) years and the mean (SD) EDSS score was 1.8 (1.0). There were no significant differences in the baseline demographics or general, clinical, NPS or MRI variables between the two treatment groups (Table 1) . Overall, 331 patients (72.1%) in the subgroup receiving sc IFNb-1a completed the three-year study: 163 received IFNb-1a, 22 mcg tiw, and 168 received IFNb-1a, 44 mcg tiw. With the exception of verbal IQ, which was significantly higher in patients who stayed on treatment for the duration of the study than in those who did not (P ¼ 0.0465), there were no significant differences in the baseline demographic, clinical, NPS and MRI characteristics, or in the assigned treatment between patients who were still under treatment at three years and those who dropped out of the study prematurely.
Dropout rates were similar in both treatment arms: 60 (26.9%) patients receiving IFNb-1a 22 mcg and 68 (28.8%) patients receiving IFNb-1a 44 mcg did not complete the study. Reasons for discontinuing were: adverse events (AEs), 13 (2.8%) patients; lost to follow up, 18 (3.9%) patients; protocol violation, 18 (3.9%) patients; lack of efficacy, 18 (3.9%) patients; pregnancy/planning to conceive, 16 (3.5%) patients; other, 45 (9.8%) patients. 'Other' reasons were predominantly subjective, such as 'patient decided not to continue'. There were no discontinuations due to injection-site reactions (ISRs).
Dropout rates for the subgroups of patients originally assigned to im IFNb-1a or IFNb-1b were as follows. A total of 51/64 patients (79.7%) receiving im IFNb-1a did not complete the study. The reasons for study discontinuation were: lost to follow up (n ¼ 25); pregnancy (n ¼ 4); and switched to another DMD (n ¼ 22). Of the 27 patients assigned sc IFNb-1b treatment, 8 (29.6%) withdrew from the study. Of these, four were lost to follow up, one withdrew due to pregnancy and three switched to another therapy.
Cognitive impairment at baseline
At study entry, 270 of 459 patients (58.8%) receiving sc IFNb-1a had impaired performance on at least one cognitive test, 172 (37.5%) patients had impaired performance on at least two tests, and 98 (21.4%) patients had impaired performance on at least three tests. Hence, the prevalence of cognitive impairment in this population was 21.4%. The proportion of patients with cognitive impairment at the baseline was higher in the 22 mcg dose group (24.2%) than in the 44 mcg group (18.6%; P ¼ 0.145). A similar trend was seen among the 318 patients for whom three-year cognitive data were available: at the baseline, 23.5% of these patients receiving IFNb-1a, 22 mcg sc tiw, were cognitively impaired, compared with 15.2% of patients receiving IFNb-1a, 44 mcg sc tiw (P ¼ 0.058).
In the subgroups of patients assigned to im IFNb-1a or sc IFNb-1b, eight patients (12.5%) and five patients (18.5%), respectively, had impaired performance on at least three tests at the baseline.
Cognitive impairment at three years
Data on cognitive function at three years were available for 318 patients (22 mcg, n ¼ 153; 44 mcg, n ¼ 165). A Cox proportional-hazards survival analysis was performed for the development of cognitive impairment over three years (Figure 1 ), and showed a 32% risk reduction for treatment with IFNb-1a 44 mcg versus 22 mcg. Kaplan-Meier survival curves confirmed the benefits of receiving the higher dose treatment over time (P ¼ 0.0109; Figure 1) .
At year 3, the proportion of patients who were cognitively impaired had increased slightly from the baseline value of 23.5% to 24.8% in the IFNb-1a 22 mcg treatment group, and had remained stable at 15.2% in the IFNb-1a 44 mcg treatment group. Hence, the proportion of patients with cognitive impairment was significantly higher in the lower dose treatment group than in the higher dose treatment group (15.2% versus 24.8%, respectively, P ¼ 0.030), although the baseline trend for a difference between these two groups must be considered.
The cognitive impairment index was significantly lower at three years than at the baseline in both treatment groups ( Table 2) , indicating improved cognitive function over the course of the study, but there were no significant differences between the two treatment groups. The Kazis' effect for each cognitive test was calculated for each treatment group (Table 3) . Similar effect sizes were seen for both treatments for all tests, with the exception of the Symbol Digit Modalities Test (SDMT; 22 mcg: -0.05, 44 mcg: 0.20).
In the subgroups of patients assigned to im IFNb-1a or sc IFNb-1b, the proportions of patients who were cognitively impaired at year 3 had increased from the baseline value in each group: from 12.5 to 23% in the im IFNb-1a group and from 18.5 to 26% in the sc IFNb-1b group. However, no further statistical analyses were performed due to the limited numbers of patients in these subgroups.
Predictors of cognitive impairment at three years
Variables that were significant in the univariate logistic regression were treatment, verbal IQ at the baseline and impaired cognitive function at the baseline, and these were included in the multivariate model. Multivariate logistic regression showed that, after correcting for baseline cognitive impairment, treatment with higher dose IFNb-1a and higher verbal IQ at the baseline were associated with a lower risk of cognitive impairment at year 3 ( Table 4 ). In addition, the model showed that impaired cognitive function at the baseline was a risk factor for cognitive impairment at year 3 ( Table 4 ).
Clinical outcomes
At year 3, complete clinical data were available for 331 patients. Sustained EDSS progression occurred in 55 of 331 (16.6%) patients. Relapse data were available for 428 (93.2%) patients at year 1, 394 (85.8%) patients at year 2, and 376 (81.9%) patients at year 3. Over the three-year study period, the mean relapse rate was 0.23 relapses per patient, and 62% of patients remained free from relapse. No significant differences were found between the two treatment groups (data not shown).
Safety
The most common AEs reported over the three-year study were consistent with the known safety profile of IFNb-1a, 28, 29 and included ISRs, FLS, headache, depression and laboratory abnormalities.
Discussion
In this study, the proportion of patients with impaired cognitive function over the three years remained stable, suggesting that treatment with IFNb-1a, 22 or 44 mcg sc tiw may prevent cognitive decline. Despite the fact that this study did not include an untreated control group, making it impossible to determine to what extent IFNb-1a prevented cognitive decline, cognitive deterioration over time has been reported in patients with MS, particularly those with existing cognitive impairment. 7 Longitudinal studies of cognitive impairment in MS are rare. In addition, differences in study design, patient populations and definitions of cognitive impairment, and the inclusion of patients receiving active treatment, 1 make it difficult to describe the natural history of MS-related cognitive decline. The findings of three studies (which included healthy volunteers as a control group) indicate that declining cognitive function can be detected over 2-5 years in both cognitively preserved and cognitively impaired patients. [30] [31] [32] In contrast, one study reported minimal cognitive decline over four years. 33 Published data suggest that the remission of cognitive symptoms is unlikely, 1,9 but we found significant improvement in the cognitive impairment index from baseline to year 3 with sc IFNb-1a, suggesting DMD treatment may improve cognitive function, at least in patients with mild physical disability. When effect-size data are considered for individual cognitive tests, positive effects of both sc IFNb-1a doses were seen at year 3 for all tests, with the exception of Word-List Generation and SDMT. Although all effects were small (the greatest Kazis' effect size was 0.39), these equated to a significant improvement in the global cognitive impairment index over the course of the study.
Thus, small improvements in the function of individual cognitive domains could result in a measurable improvement in overall cognitive performance for the patient.
The Cox regression model analyses temporal trends in outcome variables. Therefore, in this study it enabled us to show that the effects of high-dose treatment started earlier than those of the lower dose, and that the size of this effect increased over time. Indeed, the effects of sc IFNb-1a on cognitive function may be more pronounced with the high-dose treatment: the risk of cognitive impairment over three years was reduced by 32% with the 44 mcg dose compared with the 22 mcg dose. This finding was confirmed by the results of the multivariate logistic regression analysis and the significantly lower proportion of cognitively impaired patients at three years with higher, rather than lower, dose treatment. Importantly, considering the trend towards a higher proportion of patients with cognitive impairment at the baseline in the lower dose group, both the regression analyses controlled for the baseline differences between treatment groups. In addition, most Kazis' effect sizes were numerically greater in the IFNb-1a 44 mcg group than in the 22 mcg group. However, the small differences between treatment groups detected here may not be clinically relevant to the individual patient.
As with all longitudinal cognition studies, the possible influence of learning effects 34 must be considered. To minimize learning effects in our study, cognitive function was measured using the parallel, equivalent, versions of Rao's battery for serial assessments, although this may not entirely eliminate learning effects. In the absence of an untreated control group, the presumed dose effect may provide supportive evidence that IFNb-1a might stabilize cognitive function. The more pronounced effect of the higher IFNb-1a dose on cognitive decline might be taken into account by neurologists when starting DMD treatment to delay physical and cognitive worsening in patients with RRMS.
The results presented must be considered after taking into account the limitations of this study. This was an observational study in which patients were not randomized to treatment, but treatment was assigned at the physician's discretion. The study was designed and performed in accordance with the Guidelines for Good Clinical Practice in randomized, controlled trials, and it has been shown that observational studies performed in this way do not overestimate the magnitude of effects for study outcomes. 35, 36 Indeed, in the MS setting, observational studies may provide similar evidence to that obtained from Phase III trials. 36 While observational studies are more reflective of the clinical setting, there is the potential for selection bias towards treatment groups. Although treatment groups were well balanced at the baseline, a non-significant difference in baseline cognitive function was seen between groups. However, baseline cognitive performance was not an influential factor in the treatment decision-making process due to the lack of data regarding the cognitive effects of DMD treatment in patients with MS at the start of the study. We used the Cox proportional-hazards model to control for such differences, but other baseline differences that were not assessed could exist between the two groups. In addition, with the exception of the verbal IQ score, baseline patient demographics and disease and NPS characteristics did not differ between those patients who continued treatment for three years and those who discontinued treatment early. This difference in the baseline verbal IQ score was not responsible for the difference in cognitive performance at three years between the two treatment groups and did not influence the overall results of the study. The sample size may affect the study outcomes, as the three-year results in this report are from a subcohort of patients recruited to the study. As no imputation method was used for missing data, it is not known how the lack of these data affected the study results. Although high discontinuation rates can be a problem for observational studies, the proportion of patients who completed this study (72%) is comparable with data from other clinical trials. In the Phase III PRISMS (Prevention of Relapses and disability by IFNb-1a Subcutaneously in Multiple Sclerosis) study, the total study-completion rate for patients receiving sc IFNb-1a was 81% (302/373) over four years. 28 In addition, patients receiving sc IFNb-1b or im IFNb-1a were excluded from the study due to the small patient numbers in these treatment groups. The dropout rate was particularly high (79.7%) among patients receiving im IFNb-1a. Considering that over 50% of patients in this treatment group experienced relapses in the first 6-12 months of the study (data not shown), it is possible to speculate that perceived lack of efficacy and the general belief that higher and more frequent IFNb therapies are more effective than lower-dose, less-frequent treatment regimens may have contributed to this observation.
Additional limitations to this study are common to cognition studies in MS. The assessment and definition of cognitive function in patients with MS has yet to be standardized. Here, we used a validated assessment tool and a conservative definition of 'cognitive impairment', based on impairment in at least three cognitive tests, 7 with impairment on tests defined as 1 SD below normative Italian values. Furthermore, it has been suggested that cognitive changes occur too slowly to be a useful endpoint in studies of DMDs, 37 although our results do not support this view.
Few studies have investigated the effects of DMDs on cognitive function in patients with MS, and results are inconclusive. In a prospective, placebo-controlled trial, im IFNb-1a, 30 mcg qw, was shown to have protective effects on the cognitive domains most commonly affected in MS over two years of treatment; however, learning effects were reported. 34 The cognitive benefits of high dose sc IFNb-1b have also been reported following two and four years of treatment, 38 and after one year, independent of effects on clinical disease measures. 39 Glatiramer acetate has not been shown to have cognitive benefits. 40 How IFNb-1a may protect against cognitive decline is unclear. Small but consistent correlations between cognitive function and MRI disease measures have been reported, 1, 15 suggesting that inhibition of inflammation and lesion development may also preserve cognitive function. Another possibility is that IFNb may increase the production of neurotrophic factors that protect against damage due to disease processes; the IFNb-induced production of brain-derived neurotrophic factor 41 and nerve growth factor have been demonstrated. 42 The results of our study confirm that cognitive impairment is a substantial problem, even in patients with only mild physical disability: over half of all patients had impaired performance on at least one cognitive test, despite the fact that this patient cohort included only patients with 'mild' physical disability. The high incidence of cognitive impairment at the baseline, and the confirmation that this is a risk factor for ongoing cognitive impairment in later years, 31 demonstrates the importance of cognitive assessment in patients with early MS. Identifying patients with, or at risk of, cognitive decline could enable therapeutic intervention, but treatment options are currently limited to symptomatic therapies 9,43 and acetylcholinesterase inhibitors, 44 although the clinical benefits of these are yet to be confirmed.
The results reported here indicate that treatment with sc IFNb-1a may have dose-dependent cognitive benefits in mildly disabled patients with RRMS. In addition, sc IFNb-1a was shown to achieve good disease control and was well tolerated in this cohort of patients. Several studies have demonstrated the beneficial effects of early treatment on clinical disease parameters [45] [46] [47] and brain atrophy. 48 Our results further support the clinical benefit of initiating higher dose sc IFNb-1a treatment, even in patients with mild physical disability.
